JPRN-jRCT2080221417未知3 期
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Signed informed consent
- •-Histologically or cytologically confirmed Gastric or gastroesophageal junction adenocarcinoma
- •-Metastatic disease or locally advanced , unresectable disease
- •-Disease progression during or within 4 months after the last dose of the first-line therapy (platinum/fluoropyrimidine doublet with or without anthracycline)
- •-Organs are functioning well (liver, kidney, blood)
- •-Good performance status (ECOG 0 to 1)
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine - RAINBOWMetastatic gastric or gastroesophageal adenocarcinomaMedDRA version: 12.1Level: LLTClassification code 10063916Term: Metastatic gastric cancerEUCTR2010-020426-18-ROImClone LLC665
进行中（未招募）
1 期
A study to see if it is safe and helpful to add Selexipag to other PAH medication in children and adolescents.Pulmonary Arterial HypertensionEUCTR2019-002817-21-SEActelion Pharmaceuticals Ltd.237
进行中（未招募）
不适用
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis - DEFINEEUCTR2006-003696-12-BGBiogen Idec Ltd.1,011
进行中（未招募）
1 期
A study to see if it is safe and helpful to add Selexipag to other PAH medication in children and adolescents.Pulmonary Arterial HypertensionEUCTR2019-002817-21-DEActelion Pharmaceuticals Ltd.237
进行中（未招募）
不适用
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis - N/ARelapsing-Remitting Multiple SclerosisMedDRA version: 8.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2006-003696-12-CZBiogen Idec Ltd.1,011